louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01245491: The Effects of Vibration on Hypoxia
Official title: The Effects of Vibration on Hypoxia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypoxia
Lead sponsor: Institute of Aviation Medicine, Oslo, Norway
Sponsor class: OTHER_GOV
First posted: 2010-11-22
Enrollment: 13
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is:

1. To study the effect of whole-body vibration on partial pressure of oxygen in arterial blood (PaO2), under hypobaric hypoxic conditions.
2. To study the effects of whole-body vibration and hypobaric hypoxia on visual contrast sensitivity.
3. To se if there is an increase in cytokines and other biomarkers under different hypobaric hypoxic conditions Our main hypothesis is that whole-body vibration may cause PaO2 to drop to a lower level, at a given altitude; than would be the case if there were no vibration present.


Eligibility criteria: Inclusion Criteria:

Exclusion Criteria:

* Stay at altitude over 2000 m last two weeks prior to study-start.
* Severe head injury
* Cardiovascular disease
* lung disease
* Decompression sickness

Primary outcomes:
measure: PaO2
timeFrame: 14 minutes
measure: PaO2
timeFrame: 35 minutes
Secondary outcomes:
measure: Ventilation
timeFrame: 14 minutes
measure: Ventilation
timeFrame: 35 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Institute of Aviation Medicine
name: Tor A Hansen, Msc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02247791: Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty
Official title: Study of Prosthesis Choice in Older Patients With a Dislocated Femoral Neck Fracture of the Hip
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hip Fractures
Lead sponsor: Danderyd Hospital
Sponsor class: OTHER
Collaborators: name: Zimmer Biomet
First posted: 2014-09-25
Enrollment: 140
Sex: ALL
Minimum age (years): 65
Maximum age (years): 79
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate whether an uncemented hip prosthesis is as safe as an cemented hip prosthesis for patients undergoing total hip arthroplasty surgery following a displaced femoral neck fracture.

Detailed description: The study will randomize patients between an uncemented and cemented stem

Eligibility criteria: Inclusion Criteria:

* Acute Displaced femoral neck fracture
* Subject is aged between 65-79 years
* Independent walker with or without walking aides
* Subject is able and capable of providing consent to participate in the study

Exclusion Criteria:

* Patients with Rheumatoid Arthritis
* Patients with an impaired cognitive dysfunction
* Patients with Pathological fractures
* Patients with substance abuse
* Patients with fracture older than 36-hours on arrival at the A\&E
* Patients suffering from cancer
* Patients determined by principal investigator to be unsuitable for inclusion

Primary outcomes:
measure: Hip related complication rate
timeFrame: 2 years
measure: Health-related Quality of Life
timeFrame: 2 years
Secondary outcomes:
measure: Duration of surgery
timeFrame: 2 years
measure: Intraoperative bleeding
timeFrame: 2 years
measure: Hip function
timeFrame: 2 years
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Danderyd Hospital
Study officials:
affiliation: Dept of Orthopaedics, Danderyd Hospital, Stockholm, Sweden
name: Ghazi Chammout, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chammout G, Muren O, Boden H, Salemyr M, Skoldenberg O. Cemented compared to uncemented femoral stems in total hip replacement for displaced femoral neck fractures in the elderly: study protocol for a single-blinded, randomized controlled trial (CHANCE-trial). BMC Musculoskelet Disord. 2016 Sep 20;17(1):398. doi: 10.1186/s12891-016-1253-y.
Clinical trial NCT03712891: Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU
Official title: Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: PACU Length of Stay
Postoperative Nausea
Postoperative Vomiting
Patient Satisfaction
Keywords: PACU length of stay
coffee
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2018-10-19
Enrollment: 178
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of the study is to determine if providing coffee to patients who self-identify as coffee drinkers postoperatively will decrease the length of stay in the post-anesthesia care unit (PACU).

Detailed description: Decreasing the length of stay in PACU for surgical patient is a pertinent outcome. The shorter length of stay can achieve higher patient engagement scores, while simultaneously increasing the productivity of the unit. This is achieved by making more beds available for new patients coming from the operating room (OR). One thought was that coffee would benefit the investigator's patients experience through a number of pathways. Initially, the stimulant effect of coffee would create a more alert patient. A more alert patient is more likely to comprehend home care instruction and be ready for discharge earlier. Coffee is often used as a remedy for morning sickness. Ideally the act of drinking coffee or even smelling the coffee may decrease the occurrence of Post-Operative Nausea and Vomiting (PONV) in investigator's patient population. Finally, patients frequently state that the inability to drink their morning coffee is often more difficult than not being able to eat prior to surgery. By allowing those to drink coffee in PACU this would make the patient feel that they are being cared for on an emotional level, in addition to a physical level.

Eligibility criteria: Inclusion criteria:

1. 18 years old or older
2. Admitted to Bethesda North Minimally Invasive Surgery Center
3. Reports to consume at least one cup of coffee a day for at least 5 days in a week

Exclusion Criteria

1. History of PONV
2. Pre-existing cardiac arrhythmias
3. History of seizure disorder
4. Pregnant

Primary outcomes:
measure: PACU Length of Stay
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Bethesda North Hospital
state: Ohio
Study officials:
affiliation: TriHealth Inc.
name: Brandon Ballhaus, BSN, RN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03317691: The ALERT-Pilot Study
Official title: Automatic Diagnosis of ST-segment Elevated Myocardial Infarction by Artificial Intelligence-based Electrocardiographic System:The ALERT-Pilot Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Myocardial Infarction, Acute
Artificial Intelligence
ECG Pattern
Keywords: myocardial infarction
artificial Intelligence
12 lead electrocardiogram
Lead sponsor: Shanghai 10th People's Hospital
Sponsor class: OTHER
First posted: 2017-10-23
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ST segment Elevation Myocardial Infarction patients' diagnosis was confired by coronary artery angiography. The prior surgery electrocardiogram need to be collected.

Brief summary: the algorithm of artificial intelligent to diagnose myocardial infarction through prior surgery Electrocardiogram was established. The accuracy of using artificial intelligent to diagnose acute ST-segment elevation myocardial infarction and judge criminal vascular was evaluated.


Eligibility criteria: Inclusion Criteria:

1. age≥18 years old;
2. the admitting doctor's diagnosis is ST-segment Elevation Myocardial Infarction.

Exclusion Criteria:

1. the admitting diagnosis is non-ST-segment Elevation Myocardial Infarction.
2. default data;
3. pregnancy, mental disorder, kidney failure;
4. except for criteria mention above, including some improper condition considered by investigators.

Primary outcomes:
measure: the algorithm of artificial intelligent to diagnose myocardial infarction through prior surgery Electrocardiogram
timeFrame: 24 hours
measure: The accuracy of using artificial intelligent to diagnose acute ST-segment elevation myocardial infarction and judge criminal vascular
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Tenth People's Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT03677791: Virtual 360°-Tour in Coronary Computed Tomography
Official title: Virtual 360°-Tour in Coronary Computed Tomography - Effects of 360° Virtual Counselling Environment in CCTA Patient's Anxiety and Process Time
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Anxiety
Fear
Keywords: counselling
computed tomography
coronary
CT
virtual
360
anxiety
Lead sponsor: University of Oulu
Sponsor class: OTHER
Collaborators: name: Oulu University Hospital
First posted: 2018-09-19
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: RCT (Randomized controlled trial)
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of the study is to evaluate the effectiveness of the virtual 360° counselling environment in the anxiety and process time of the patients coming to CCTA (coronary computed tomography angiography). The virtual, 360° environment 'Virtual 360°-tour in coronary computed tomography' uses 360°- technology based on spherical panorama images and resembles the spaces of the hospital according to the patient's pathway in CT-examination and provides information to the patient at various stages of the pathway.

Detailed description: The purpose of the study is to evaluate the effectiveness of the virtual 360° counselling environment in the anxiety and process time of the patients coming to CCTA (coronary computed tomography angiography).

The virtual, 360° environment 'Virtual 360°-tour in coronary computed tomography' uses 360°- technology based on spherical panorama images and resembles the spaces of the hospital according to the patient's pathway in CT-examination and provides information to the patient at various stages of the pathway. Patients who have referred first time to the coronary computed tomography can access the virtual CT examination environment via link before entering the hospital. Using the environment requires a network connection and is possible with a computer, tablet or phone. The environment has digital counselling materials in text, image, animation and video formats in three different virtual spaces/views, the environment and examination are presented via pathway of example 59-year female patient with arterial hypertension and exercise related chest pain (angina pectoris).

Eligibility criteria: Inclusion Criteria:

* coming to first coronary computed tomography examination
* adult patient
* able to independently fill in question forms

Exclusion Criteria:

* previous coronary computed tomography
* mental illness

Primary outcomes:
measure: anxiety measured with State-Trait Anxiety Inventory for adults (STAI)
timeFrame: 1 month
Secondary outcomes:
measure: CCTA Process time
timeFrame: 1 month
Other outcomes:
Locations:
city: Oulu
country: Finland
facility: Oulu University Hospital
Study officials:
References:
Clinical trial NCT07017491: Determination of Glycemic Index and Glycemic Load of Selected Melon Varieties in Healthy Adults
Official title: A Randomized, Open-Label, Cross-Over Study to Determine the Glycemic Index and Glycemic Load of Selected Melon Varieties in Healthy Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Glycemic Index
Glycemic Load
Keywords: GLYCEMIC LOAD
Lead sponsor: Rehman Medical Institute - RMI
Sponsor class: OTHER
First posted: 2025-06-12
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This crossover study aims to determine and compare the glycemic index (GI) and glycemic load (GL) of different melon varieties in healthy adults. Using glucose as the reference food, participants will consume test portions of each melon variety containing equivalent amounts of available carbohydrates.

Detailed description: This crossover study aims to determine and compare the glycemic index (GI) and glycemic load (GL) of different melon varieties in healthy adults. Using glucose as the reference food, participants will consume test portions of each melon variety containing equivalent amounts of available carbohydrates. Blood glucose levels will be monitored at regular intervals over a 2-hour period. The glycemic response will be used to calculate GI and GL values for each melon type. The study is intended to inform dietary recommendations for blood glucose management.

Eligibility criteria: Inclusion Criteria:

1) Healthy males and females aged 18-50 years. 2) Body mass index (BMI) :Normal BMI (18-24.9) 3) Willingness to follow dietary instructions and attend all testing sessions

* Exclusion Criteria:

  1. Individuals with known metabolic disorders (e.g., diabetes, metabolic syndrome).
  2. Use of medications or supplements affecting blood glucose.
  3. Allergy or intolerance to melon or glucose solutions.
  4. Not able to co ordinate

Primary outcomes:
measure: Glycemic Index (GI) of Melon Varieties
timeFrame: 1 month
Secondary outcomes:
measure: Glycemic Load (GL) of Melon Varieties
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05044091: Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
Official title: Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ovarian Cancer
HRD
PARP Inhibitor
Keywords: Ovarian caner, HRD, PARP inhibitor
Lead sponsor: Jiangsu Cancer Institute & Hospital
Sponsor class: OTHER
First posted: 2021-09-14
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Ovarian/fallopian tube/primary peritoneal cancer patients treated with PARP inhibitor in the real word.

Brief summary: Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

Detailed description: This study intends to perform HRD testing of ovarian cancer in real world from China and correlate HRD status and clinical characteristics with therapeutic outcomes.

Eligibility criteria: Inclusion Criteria:

1. Subjects join the study voluntarily and sign informed consent;
2. Female subjects are older than 18 years;
3. ECOG(Eastern Cooperative Oncology Group) physical status score is 0-2;
4. Life expectancy≥3 months;
5. Histologically confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous or endometrioid histology;
6. Patients received PARP inhibitor as maintenance therapy or monotherapy for more than four weeks.

Exclusion Criteria:

1. Personnel involved in the formulation or implementation of the research plan;
2. Patient participated in other clinical trails using other experimental drugs at the same time as the study;
3. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ;
4. Previous or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML);
5. Patients who are pregnant or lactation, or who plan to become pregnant during study treatment.

Primary outcomes:
measure: Overall Response Rate (ORR)
timeFrame: Through study completion, an average of 1 year
measure: Progression Free Survival (PFS)
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Xiaoxiang Chen, MD,PhD
state: Jiangsu
Study officials:
affiliation: Jiangsu Cancer Institute & Hospital
name: Xiaoxiang Chen, MD,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00724191: Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
Official title: Quantitation of Human Brain Tumor Therapy Response by MR
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Tumors
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2008-07-29
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over of 18 who have been diagnosed with a brain tumor of the central nervous system. Patients must have a treatment plan for their brain tumor from their physician.

Brief summary: The purpose of this study is to determine if new MRI methods that measure various information and chemical makeup in the brain, will give early information regarding response to treatment in patients with brain tumors.

Detailed description: The purpose of this study is to see if new MRI methods which measure information related to water, blood flow, and chemical makeup in the brain, can give early information of how well treatment is working in patients with brain tumors.

Eligibility criteria: Inclusion Criteria:

* Patients over the age of 18 who have been diagnosed with a brain tumor of the central nervous system and a treatment plan has been discussed.
* Must be willing/able to undergo 3-5 MRI scans with IV contrast.
* You can take part in this study if you are NOT afraid of small, enclosed places.

Exclusion Criteria:

* A patient who is claustrophobic.
* Females who are pregnant or lactating.
* Patients who have electrically, magnetically or mechanically activated implants such as heart pacemaker, magnetic surgical clips, prosthesis or or implanted neurological stimulator.
* Any patient who has a history of allergic reactions to MR contrast agent (Omniscan, Magnevist, MultiHance)
* Patients who require general anesthesia to complete MRI exam or patients who have had a negative reaction to MRI sedation. (Chloral Hydrate, Pentobarbital or Versed)
* You should NOT have any metals, or implanted devices in your body (such as aneurysm clips, pacemakers, or artificial joints or limbs.). You will need to tell us about your medical history including any surgeries you have had.

Also, if your job or any other experience might have left metal fragments in your body, please let us know, as the MRI has a strong magnetic field could move a metal fragment in your body or interfere with an implanted device, such as a pacemaker, causing you harm.

Primary outcomes:
measure: MRI metrics for brain tumor response
timeFrame: approximately 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: Univeristy of Michigan Health System
state: Michigan
Study officials:
affiliation: University of Michigan
name: Thomas L. Chenevert, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01652391: Modulation of Cognitive Control by Transcranial Direct Current Stimulation
Official title: Modulation of Cognitive Control in Healthy and Depressed Subjects by Transcranial Direct Current Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depression
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
First posted: 2012-07-30
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Insufficient cognitive control over emotional distracters is characteristic for major depressive disorder (MDD). Hypoactivation of the dorsolateral prefrontal cortex (dlPFC) is associated with this deficit. In this study the investigators assess the effect of an enhancement of dlPFC activity in MDD patients by anodal transcranial direct current stimulation (tDCS) on cognitive control.

In a double-blinded, balanced randomized, sham-controlled crossover trial the investigators determine the effect of a single-session tDCS to the left dlPFC on cognitive control in MDD patients and healthy controls. To assess the cognitive control the investigators use a delayed response working memory (DWM) task with pictures of varying valence presented during the delay period.


Eligibility criteria: Inclusion Criteria:

* age \> 18
* informed consent
* in the patients group: Major depressive disorder, no antidepressant medication or stability over 1 week

Exclusion Criteria:

* seizures
* cardiac pacemaker
* deep brain stimulation

Primary outcomes:
measure: Correctness of response
timeFrame: The primary outcome measure is obtained during the intervention (20min tDCS or sham stimulation).
Secondary outcomes:
measure: Reaction time
timeFrame: The secondary outcome measure is obtained during the intervention (20min tDCS or sham stimulation).
Other outcomes:
Locations:
city: Tübingen
country: Germany
facility: Universitiy Hospital Tübingen
Study officials:
References:
citation: Wolkenstein L, Plewnia C. Amelioration of cognitive control in depression by transcranial direct current stimulation. Biol Psychiatry. 2013 Apr 1;73(7):646-51. doi: 10.1016/j.biopsych.2012.10.010. Epub 2012 Dec 6.